Takeda has elected to nix all manufacturing of its Natpara injection for hypoparathyroidism in the U.S. and abroad by the end of 2024. After an indefinite commercial delay on its Shire-acquired ...

From the commercial standpoint, Takeda and Protagonist project Rusfertide to generate up to $1-2 billion in the U.S. at peak sales (see image below). Given the current partnership agreement, ...

Takeda Pharmaceuticals struck a deal with AcuraStem to purchase its amyotrophic lateral sclerosis (ALS) treatment program on Monday. Per terms of the transaction, the Japanese pharma giant will ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award.This prestigious global award ...

Under the terms of the Takeda agreement, Protagonist is responsible for the phase 3 programme and regulatory filing in the US, while the Japanese drugmaker takes on all regulatory and commercial ...

Harmony Biosciences has named Adam Zaeske its next chief commercial officer, luring the Takeda veteran back from Europe to lead a push to turn Wakix into a blockbuster and prepare to launch other ...

Takeda delivered US$203 million in net sales of FRUZAQLA ® in the nine months ended September 2024. This US$20 million payment will be the first ever commercial milestone payment received by ...

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) is the largest Japanese pharmaceutical company and holds a leading position in the global immunoglobulins market. In recent months, the company's share ...

Under the agreement, Takeda will pay Hutchmed $400 million up front and up to $730 million in additional potential payments relating to regulatory, development, and commercial sales milestones, as ...

They chose Takeda because they believe the Japanese pharma giant has the development and commercial infrastructure to maximize the asset’s value by pursuing broader opportunities than Keros ...